	AllExperts > Oncology (General Cancer)
	Search

About Claes-Gustaf Nordquist, M.D.
Expertise
Questions concerning Cancer, Oncology, radiation Therapy, Tumours, Chemotherapy, Cytotoxic Drugs, Hormonal Therapy, Radiation Protection.

Experience
I'm a Doctor of Medicine. Licensed/certified physician and surgeon and specialist in Medical Oncology and Radiation therapy in Sweden, Denmark, Finland, Iceland, Norway and the European Union. Background in Radiation Therapy, Medical Oncology, Radiation Protection, Nuclear Medicine, Diagnostic Radiology, Gynecological Oncology, Clinical Pathology, Clinical Cytology,Hematology and Internal Medicine. M.D. from the faculty of medicine, Royal Karolinska Institute, Stockholm, Sweden. Have also been an exchange student at the Hebrew University, Hadassah Medical School, Jerusalem Israel. Former medical consultant, Swedish National Board of Radiation Protection. Former Police Surgeon and Medical Examiner, Stockholm Police Department. Former Chief Medical Officer, The Royal Guards, The Royal Horse Guards and the Royal Household Brigade, Royal Swedish Army Medical Corps. Now in private practice in Stockholm, Sweden. I also answer questions in these other categories: General History, Military History, Brain Tumors, Breast Cancer, Colon Cancer

You are here: Experts > Health/Fitness > Medical Specialists > Oncology (General Cancer) > Squamous cell lung cancer

Oncology (General Cancer) - Squamous cell lung cancer

Expert: Claes-Gustaf Nordquist, M.D. - 11/3/2009

Question
I am wondering if the following first line chemotherapy schedule should be considered for a patient diagnosed with stage 3b squamous NSCLC:

Taxotere 30mg/m2 days 1,8,15
Gemzar 750mg/m2 days 1,8,15

Answer
It could at least be considered. I normally do not comment on details of chemotherapy here for the simple reason that I'm retired and the progress of chemotherapy is so swift that it is hopeless to try to keep up with its details unless you are yourself busy with it all the time. And that I'm not due to my retirement after a stroke. So for a more up to date opinion you should discuss this with someone still active with this kind of treatment.

Add to this Answer Ask a Question